IRWD earnings analysis
What we found in IRWD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ironwood Pharmaceuticals reported a strong Q1 2026, beating revenue estimates with total revenues of $106.5 million and achieving diluted EPS of $0.24, surpassing the forecast of $0.21. The company maintains its full-year revenue guidance of $450 million to $475 million, signaling confidence in sustained performance due to strong sales from LINZESS.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surged by 258%
- Total revenue reached $106.5 million, up from $41.1 million in Q1 2025.
- EPS Outperformed Expectations
- Diluted EPS was reported at $0.24, exceeding the consensus estimate of $0.21.
- Decreased Operating Expenses
- Operating expenses totaled $33.9 million, down from $70.3 million year-over-year.
- Strong LINZESS Performance
- Increased revenues of $65.5 million attributed to enhanced net pricing and prescription demand for LINZESS.
- Positive Net Income Reported
- Net income for Q1 2026 was $40.8 million, a turnaround from a loss of $37.4 million in Q1 2025.
- Improved Cash Flow
- Operating cash flow for the quarter was positive at $5.1 million, although down from $20 million a year ago.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Rising Interest Expenses
- Interest expense increased to $9.1 million from $8.1 million in Q1 2025.
- Accumulated Deficit Remains High
- The company has an accumulated deficit of approximately $1.6 billion as of March 31, 2026.
- High Dependency on LINZESS
- Revenues are primarily dependent on LINZESS, raising concerns over market competition risks.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.24
- Segment
- LINZESS sales
- Segment
- collaborative arrangements revenue
What they said about what is next.
Full-year 2026 revenue guidance maintained at $450M to $475M.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Ironwood Pharmaceuticals, Inc. reported a total revenue of $296.2 million for the year ended December 31, 2025, a decline from $351.4 million in 2024, primarily due to a $51.1 million decrease in profit shares from…
- 10-Q · November 10, 2025
- Ironwood Pharmaceuticals reported impressive Q3 2025 results, with revenues of $122.06 million, significantly surpassing expectations and marking a notable 94.5% increase from the prior quarter and a 32.7% increase…
- 10-Q · August 11, 2025
- Ironwood Pharmaceuticals reported strong Q2 2025 results with net income of $23.6 million compared to a loss of $0.9 million in Q2 2024. Revenue surged to $85.2 million, up from $75 million in Q1 2025, primarily driven…
- 10-Q · May 12, 2025
- Ironwood Pharmaceuticals reported a significant decline in revenue and higher losses in Q1 2025 compared to the previous year. Total revenue dropped to $41.1 million from $74.9 million a year ago, while net losses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IRWD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever